Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Lisa Soyeon Park"'
Autor:
Martin Demarchi, Pierre Coliat, Kristi Mclendon, Jocelyn Chung Shii Hii, Peggy Feyaerts, Felicia Ang, Litha Jaison, Filip Deforce, Marie Paule Derde, Michael Jinwoo Kim, Lisa Soyeon Park, Alexandre Detappe, Xavier Pivot
Publikováno v:
Pharmacology Research & Perspectives, Vol 9, Iss 4, Pp n/a-n/a (2021)
Abstract Prestige Biopharma Ltd (Singapore) has developed HD201, a proposed biosimilar to reference product trastuzumab. As a part of the stepwise approach to ensure comparability between the biosimilar candidate and the reference medicinal product,
Externí odkaz:
https://doaj.org/article/81e0d5aa8ebc42d8a35ba3783ef70e13
Autor:
Martin Demarchi, Pierre Coliat, Philippe Barthelemy, Roland Schott, Meher BenAbdelghani, Michael Kim, Jocelyn Chung Shii Hii, Peggy Feyaerts, Felicia Rui Xia Ang, Marie Paule Derde, Filip Deforce, Thierry Petit, Chris Schwabe, Chris Wynne, Lisa Soyeon Park, Xavier Pivot
Publikováno v:
PLoS ONE, Vol 16, Iss 9, p e0248222 (2021)
PurposeThis first-in-human study was designed to evaluate the pharmacokinetic (PK) equivalence between HD204 and the European Union (EU)-sourced bevacizumab, between HD204 and the United States of America (US)-sourced bevacizumab, and between EU-sour
Externí odkaz:
https://doaj.org/article/45bef64f51cc46f89c05d51ff1082315
Publikováno v:
Journal of Pharmacological Sciences, Vol 132, Iss 1, Pp 41-47 (2016)
Rheumatoid arthritis (RA) research has been largely dependent on collagen induced arthritis (CIA) rodent models, however, they may not translate well to humans due to innate differences in the size, physiology and lifespan. The present study aimed to
Externí odkaz:
https://doaj.org/article/c8ecc4fa3bdd40009ae97b20017a4ff0
Autor:
Michael Jinwoo Kim, Peggy Feyaerts, Marie Paule Derde, Alexandre Detappe, Litha Jaison, Felicia Ang, Filip Deforce, Jocelyn hii, Martin Demarchi, Lisa Soyeon Park, Xavier Pivot, Kristi Mclendon, Pierre Coliat
Publikováno v:
Pharmacology Research & Perspectives. 9
Prestige Biopharma Ltd (Singapore) has developed HD201, a proposed biosimilar to reference product trastuzumab. As a part of the stepwise approach to ensure comparability between the biosimilar candidate and the reference medicinal product, a phase I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1cde9de3255d5a6fdb2aa023ab4d3351
https://doi.org/10.1002/prp2.839
https://doi.org/10.1002/prp2.839
Autor:
Won-Jae Lee1, Lisa Soyeon Park2 pwggeneticslisa@gmail.com
Publikováno v:
Korean Journal of Veterinary Research. 2018, Vol. 58 Issue 3, p131-136. 6p.
Autor:
M. Benabdelghani, Xavier Pivot, Lisa Soyeon Park, Pierre Coliat, Marie Paule Derde, Philippe Barthélémy, Thierry Petit, Roland Schott, Chris Wynne, Jocelyn hii, Michael Kim, Filip Deforce, Peggy Feyaerts, Felicia Ang, Christopher Schwabe, Martin Demarchi
Publikováno v:
PLoS ONE, Vol 16, Iss 9, p e0248222 (2021)
PLoS ONE
PLoS ONE
Purpose This first-in-human study was designed to evaluate the pharmacokinetic (PK) equivalence between HD204 and the European Union (EU)-sourced bevacizumab, between HD204 and the United States of America (US)-sourced bevacizumab, and between EU-sou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b35d486e113967fe975dc8af0592591
https://doi.org/10.1371/journal.pone.0248222
https://doi.org/10.1371/journal.pone.0248222
Publikováno v:
Korean Journal of Veterinary Research. 56:177-181
Mini-pigs have been widely employed in preclinical studies to explore new therapeutic strategies for diseases of the human urinary system; however, the normal reference of the renal artery has not been clearly investigated in the mini-pig model. Ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f7af35e9e7374d9df7b05b8922a32441
https://doi.org/10.14405/kjvr.2016.56.3.177
https://doi.org/10.14405/kjvr.2016.56.3.177
Autor:
Xavier Pivot, Felicia Ang, Peggy Feyaerts, Martin Demarchi, Lisa Soyeon Park, Pierre Coliat, Jeong-Hyeon Lee, Michael Kim, Filip Deforce, Kristi Mclendon, Marie Paule Derde, Jocelyn hii, Kuo Wei Chan
Publikováno v:
Journal of Clinical Oncology. 38:579-579
579 Background: Trastuzumab, an approved prescription drug by EMA and FDA under the name Herceptin has become the key treatment in patients with HER2−positive breast cancer. HD201, developed by Prestige Biopharma Pte Ltd is a biosimilar candidate t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26bcfcf116d9b571f7fc157f8aca4b70
https://doi.org/10.1200/jco.2020.38.15_suppl.579
https://doi.org/10.1200/jco.2020.38.15_suppl.579
Autor:
Pierre Coliat, Michael Kim, Xavier Pivot, Peggy Feyaerts, M. Benabdelghani, Martin Demarchi, Philippe Barthélémy, Lisa Soyeon Park, Marie Paule Derde, Kuo Wei Chan, Felicia Ang, Filip Deforce, Jocelyn hii, Roland Schott
Publikováno v:
Journal of Clinical Oncology. 38:e21556-e21556
e21556 Background: Prestige Biopharma Pte Ltd is developing HD204, a biosimilar candidate of Bevacizumab (Avastin). Bevacizumab has been approved in the treatment of a variety of metastatic tumours. Bevacizumab, a recombinant humanized monoclonal ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f668fab82644fef193baed6b036af6a
https://doi.org/10.1200/jco.2020.38.15_suppl.e21556
https://doi.org/10.1200/jco.2020.38.15_suppl.e21556
Autor:
Lisa Soyeon Park, Xavier Pivot, Jeong-Hyeon Lee, Michael Kim, Jocelyn hii, Felicia Ang, Kuo Wei Chan, Peggy Feyaerts
Publikováno v:
Journal of Clinical Oncology. 37:e12505-e12505
e12505 Background: Trastuzumab, an approved prescription drug by EMA and FDA under the name Herceptin has become the key treatment in patients with HER2 positive breast cancer. HD201, developed and owned by Prestige Biopharma Pte Ltd is a biosimilar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fd68dfc83061b457c0ad5baed9dfc780
https://doi.org/10.1200/jco.2019.37.15_suppl.e12505
https://doi.org/10.1200/jco.2019.37.15_suppl.e12505